Inovio Pharmaceuticals Inc Share Price Nyse
Equities
US45773H1023
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
01:59pm | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
05-13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Sales 2024 * | 604K 48.11M | Sales 2025 * | 8.03M 640M | Capitalization | 294M 23.44B |
---|---|---|---|---|---|
Net income 2024 * | -99M -7.88B | Net income 2025 * | -93M -7.41B | EV / Sales 2024 * | 487 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.6 x |
P/E ratio 2024 * |
-2.95
x | P/E ratio 2025 * |
-3.76
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 24/03/19 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 31/05/02 |
Chief Tech/Sci/R&D Officer | - | 31/01/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 30/11/03 |
Lota Zoth
BRD | Director/Board Member | 64 | 31/12/17 |
Jay Shepard
BRD | Director/Board Member | 65 | 14/01/20 |
1st Jan change | Capi. | |
---|---|---|
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+45.09% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |